IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Stacy R. Lindborg, President and chief executive officer of IMUNON

“This data provides a compelling immunological explanation for the survival benefit we observed in OVATION 2”

Stacy R. Lindborg, President and chief executive officer of IMUNON

“Seeing a consistent, treatment-driven shift in the tumor immune microenvironment in patient biopsies, rather than in a preclinical model, is an important validation of our TheraPlas platform.”

Stacy R. Lindborg, President and chief executive officer of IMUNON

“Presenting this work at SITC, the premier forum for cancer immunotherapy, reflects the growing scientific interest in our approach as we advance the pivotal Phase 3 OVATION 3 trial.”

Douglas V. Faller, Chief medical officer of IMUNON

“The central challenge in epithelial ovarian cancer has been its highly immunosuppressive tumor microenvironment, which has limited the effectiveness of immune therapies such as checkpoint inhibitors”

Douglas V. Faller, Chief medical officer of IMUNON

“What these paired serial patient biopsies show is that IMNN-001 delivers IL-12 where it is needed and dramatically remodels local immune balance in favor of the patient (from “cold” to immunologically “hot”), with minimal systemic IL-12 exposure and a highly favorable safety and tolerability profile.”

Douglas V. Faller, Chief medical officer of IMUNON

“The complementary contributions of IMNN-001 and chemotherapy observed in this analysis help explain why this combination has translated into a survival benefit in the clinic.”